Skip to main content

Table 1 Demographics

From: Albumin infusion rate and plasma volume expansion: a randomized clinical trial in postoperative patients after major surgery

  Slow infusion (n = 33) Rapid infusion (n = 31)
Gender (female) 25 (76) 16 (52)
Age, years 69 (65–74) 68 (55–74)
BMI, kg/m2 25 (23–30) 25 (23–27)
ASA class 1 0 2 (6)
ASA class 2 22 (65) 21 (68)
ASA class 3 11 (33) 8 (26)
Inclusion criteria
 PLR 23 (70) 20 (65)
 ScvO2 10 (29) 9 (29)
 Lactate 21 (62) 20 (65)
 Urine production 13 (38) 13 (42)
 Systolic blood pressure 9 (27) 8 (26)
Operation time, min 368 (289–479) 418 (365–467)
Intraoperative bleeding, ml 600 (300–1000) 500 (300–1000)
Epidural analgesia 29 (88) 30 (97)
Intraoperative fluids
 Crystalloids, ml 4250 (4000–5250) 4250 (3500–5250)
 Colloids, ml 500 (500–1000) 700 (250–1000)
Pre-treatment hemodynamics
 HR, beats/min 84 (74–93) 88 (71–97)
 Systolic blood pressure, mmHg 114 (96–125) 112 (99–129)
 MAP, mmHg 77 (68–90) 77 (68–88)
 CVP, cmH2O 3 (0–6) 3 (−1–8)
 Urine production, ml/kg/h 0.8 (0.4–2.2) 0.8 (0.5–1.0)
Pre-treatment laboratory data
 Albumin, g/l 31 (28–34) 33 (31–35)
 Lactate, mmol/l 2.2 (1.7–3.1) 2.7 (1.5–3.2)
 ScvO2, % 73 (67–76) 73 (68–78)
 Hct (%) 36 (34–38) 35 (32–39)
Glycocalyx components and hormones
 Hyaloronan, ng/ml 153 (125–200) 174 (132–208)
 Syndekan-1, ng/ml 56 (32–96) 91 (54–190)
 Glypican-4, ng/ml 13 (10–17) 13 (10–21)
 Copeptin, pmol/l 138 (75–244) 113 (71–207)
 MR-proANP, pmol/l 85 (61–106) 94 (71–139)
 Renin, mU/l 51 (23–144) 40 (19–131)
Norepinephrine at the time of inclusion 3 (9) 1 (3)
  1. Data are presented as number (percent) or median and interquartile range unless stated otherwise
  2. Abbreviations: BMI body mass index, PLR passive leg raising, ScvO2 central venous saturation, HR heart rate, MAP mean arterial pressure, CVP central venous pressure, BE base excess, ScvO2 central venous oxygen saturation, Hct hematocrit, MR-pro-ANP mid-regional pro-atrial natriuretic peptide